Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.

Makaleler > Tam Makale · 2009

Yazarlar: GV SCAGLIOTTI, K PARK, S PATIL, J ROLSKI, Tuncay GÖKSEL, R MARTINS, SJ GANS, C VISSEREN-GRUL, P PETERSON

European journal of cancer (Oxford, England : 1990), SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2009, cilt 45, ss 2298-2303